NCT07418203

Brief Summary

Today, cancers associated with papillomavirus infection affect 6,300 new people each year in France, men and women combined. The papillomavirus vaccine is currently the only vaccine that protects against HPV-associated cancers. However, in its report on vaccination coverage for 2024, Santé Publique France reveals that 41.5% and 37.4% of the 18- and 19-year-old French population respectively have a complete vaccination schedule. Information, education and communication about HPV are essential to enable the entire population to make informed and responsible decisions about HPV. Increasing information and immunization coverage for papillomavirus is part of the government's ambitious health plans with the national sexual health strategy and college vaccination campaign.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
29

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Dec 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2025

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

February 6, 2026

Completed
12 days until next milestone

First Posted

Study publicly available on registry

February 18, 2026

Completed
Last Updated

February 18, 2026

Status Verified

February 1, 2026

Enrollment Period

2 months

First QC Date

February 6, 2026

Last Update Submit

February 10, 2026

Conditions

Keywords

HPVHPV vaccinationknowledge of young

Outcome Measures

Primary Outcomes (1)

  • Knowledge about HPV and anti-HPV vaccination

    Knowledge about HPV and anti-HPV vaccination will be assessed by a questionnaire developed by a team of midwives and methodologists. Questions will address: Knowledge about HPV infection Knowledge of prevention measures Knowledge about HPV vaccination

    Day 0

Interventions

Data collection

Eligibility Criteria

Age18 Years - 19 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

girls and boys aged 18 to 19 years old

You may qualify if:

  • Boys and girls 18 to 19 years of age Vaccinated or not against HPV Sexually active or not Agreeing to take part in the study

You may not qualify if:

  • Minors Age 20 and over Protected by law (guardianship, curatorship, safeguard of justice) Not wishing to answer the questionnaire

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ufr Medecine Urca

Reims, 51100, France

Location

MeSH Terms

Interventions

Data Collection

Intervention Hierarchy (Ancestors)

Epidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 6, 2026

First Posted

February 18, 2026

Study Start

December 1, 2024

Primary Completion

February 1, 2025

Study Completion

July 1, 2025

Last Updated

February 18, 2026

Record last verified: 2026-02

Locations